Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hemachudha, T.
Right arrow Articles by Johnson, R. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hemachudha, T.
Right arrow Articles by Johnson, R. T.
NEUROLOGY 1988;38:375
© 1988 American Academy of Neurology

Immunologic studies of rabies vaccination-induced Guillain-Barré syndrome

Thiravat Hemachudha, MD, Diane E. Griffin, MD, PhD, Winston W. Chen, PhD and Richard T. Johnson, MD

From the Department of Medicine (Dr. Hemachudha), Chulalongkorn University Hospital, Bangkok, Thailand; and the Departments of Neurology (Drs. Hemachudha, Griffin, and Johnson) and Medicine (Dr. Griffin), and The Kennedy Institute (Dr. Chen), The Johns Hopkins University School of Medicine, Baltimore, MD.

Patients with Guillain-Barré syndrome (GBS) induced by rabies vaccines prepared from either suckling mouse brain (SMB) or mature sheep brain (Semple vaccine) and patients with sporadic, idiopathic GBS were studied for antibody to myelin basic protein (MBP), P2 protein, and Schwann cells. Sera from all four Semple vaccine- and one of five SMB vaccine-induced GBS patients, but none of the sporadic GBS patients, had antibody to MBP. Sera from Semple vaccinees also had antibody to fixed, transformed Schwann cells, but similar amounts of antibody were found in sera from Semple vaccinees with CNS complications and with minor non-neurologic complications, suggesting that this antibody was not specifically linked to the development of polyneuritis. None of the sera had detectable antibody to P2 protein. We conclude that patients with GBS constitute a heterogeneous population and that different target antigens may serve as a focus for this presumed autoimmune disease.

Address correspondence and reprint requests to Dr. Griffin, Department of Neurology, Meyer 6–181, The Johns Hopkins University School of Medicine, Baltimore, MD 21205.

Supported by grants from the National Multiple Sclerosis Society, the National Institutes of Health (HD10981) and Chulalongkorn University and a Fogarty Fellowship to Dr. Hemachudha.

Received March 31, 1987. Accepted for publication in final form June 23, 1987.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by AAN Enterprises, Inc.